Phase I Study of PM54 Administered to Patients with Advanced Solid Tumors

2024-517579-19-00 Protocol PM54-A-002-24 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 24 Mar 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 6 sites · Protocol PM54-A-002-24

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 540
Countries 1
Sites 6

Selected Advanced Solid Tumors

Key facts

Sponsor
Pharma Mar S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
24 Mar 2025 → ongoing
Decision date (initial)
2025-03-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Selected Advanced Solid Tumors

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pharma Mar S.A.

Sponsor organisation
Pharma Mar S.A.
Address
Avenida De Los Reyes 1, Poligono Industrial La Mina Poligono Industrial La Mina
City
Colmenar Viejo
Postcode
28770
Country
Spain

Scientific contact point

Organisation
Pharma Mar S.A.
Contact name
Clinical Development Oncology Unit

Public contact point

Organisation
Pharma Mar S.A.
Contact name
Clinical Development Oncology Unit

Locations

1 EU/EEA country · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 120 6
Rest of world
United States, China, United Kingdom
420

Investigational sites

Spain

6 sites · Ongoing, recruiting
Hospital Son Llatzer
Oncology, Carretera De Manacor Km 4, 07198, Palma
MD Anderson Cancer Center
Oncology, Calle De Arturo Soria Nº 270, 28033, Madrid
University Hospital Virgen Del Rocio S.L.
Oncology, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Hm Nou Delfos
START Barcelona- HM Nou Delfos, Avinguda De Vallcarca 151, 08023, Barcelona
Hospital Universitario Quironsalud Madrid
NEXT Madrid Phase I trials, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario De Torrejon
Oncology, Calle De Mateo Inurria 1, 28850, Torrejon De Ardoz

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-03-24 2025-03-25

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-22 Spain Acceptable with conditions
2025-03-08
2025-03-08
2 SUBSTANTIAL MODIFICATION SM-1 2025-04-10 Spain Acceptable
2025-05-26
2025-05-26
3 SUBSTANTIAL MODIFICATION SM-2 2025-12-18 Spain Acceptable
2026-03-23
2026-03-30
4 SUBSTANTIAL MODIFICATION SM-3 2026-04-01 Spain Acceptable
2026-05-18
2026-05-22